Levofloxacin (Levaquin)
levofloxacin — the S-enantiomer of ofloxacin; formerly marketed as Levaquin
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Nosocomial pneumonia | Adults | Monotherapy (add anti-pseudomonal beta-lactam if Pseudomonas suspected) | FDA Approved |
| Community-acquired pneumonia (including MDRSP) | Adults | Monotherapy | FDA Approved |
| Complicated skin and skin structure infections | Adults | Monotherapy | FDA Approved |
| Chronic bacterial prostatitis | Adults | Monotherapy | FDA Approved |
| Complicated UTI and acute pyelonephritis | Adults | Monotherapy | FDA Approved |
| Uncomplicated UTI | Adults (reserve for no alternative) | Monotherapy | FDA Approved |
| Inhalational anthrax (post-exposure) | Adults and pediatrics ≥6 months | First-line | FDA Approved |
| Plague (Y. pestis) | Adults and pediatrics ≥6 months | First-line | FDA Approved |
| Acute bacterial sinusitis and AECB | Adults (reserve for no alternative) | Monotherapy | FDA Approved |
Levofloxacin is a third-generation “respiratory” fluoroquinolone distinguished from ciprofloxacin by its enhanced activity against Streptococcus pneumoniae (including multi-drug-resistant strains), atypical respiratory pathogens (Legionella, Mycoplasma, Chlamydophila), and its near-complete oral bioavailability (~99%), allowing seamless IV-to-oral switching. These properties have made it a first-line choice in guideline-recommended treatment of community-acquired pneumonia. As with all fluoroquinolones, its use for uncomplicated UTI, acute sinusitis, and AECB is restricted to patients with no alternative treatment options per the FDA boxed warning.
Tuberculosis (MDR-TB): Used as part of multi-drug regimens for drug-resistant TB. WHO-recommended. Evidence quality: High.
Spontaneous bacterial peritonitis prophylaxis: Alternative to norfloxacin in cirrhosis. Evidence quality: Moderate.
Travellers’ diarrhea: Single-dose or short-course therapy. Evidence quality: Moderate.
H. pylori eradication (salvage): In levofloxacin-containing triple or quadruple regimens. Evidence quality: Moderate.
Dosing
Adult Dosing by Clinical Scenario (CrCl ≥50 mL/min)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Nosocomial pneumonia | 750 mg q24h | 750 mg q24h | 750 mg q24h | 7–14 days (FDA PI) Add anti-pseudomonal beta-lactam if Pseudomonas suspected |
| CAP — standard regimen (including MDRSP) | 500 mg q24h | 500 mg q24h | 500 mg q24h | 7–14 days (FDA PI) |
| CAP — short-course high-dose | 750 mg q24h | 750 mg q24h | 750 mg q24h | 5 days (FDA PI); excludes MDRSP |
| Complicated skin & skin structure | 750 mg q24h | 750 mg q24h | 750 mg q24h | 7–14 days |
| Uncomplicated skin & skin structure | 500 mg q24h | 500 mg q24h | 500 mg q24h | 7–10 days |
| Chronic bacterial prostatitis | 500 mg q24h | 500 mg q24h | 500 mg q24h | 28 days (FDA PI) |
| Complicated UTI / pyelonephritis (5-day) | 750 mg q24h | 750 mg q24h | 750 mg q24h | 5 days (FDA PI) |
| Complicated UTI / pyelonephritis (10-day) | 250 mg q24h | 250 mg q24h | 250 mg q24h | 10 days (FDA PI) |
| Uncomplicated UTI (reserve) | 250 mg q24h | 250 mg q24h | 250 mg q24h | 3 days; use only if no alternative (FDA boxed warning) |
| Acute bacterial sinusitis (5-day) | 750 mg q24h | 750 mg q24h | 750 mg q24h | 5 days; reserve for no alternative |
| Acute bacterial sinusitis (10–14 day) | 500 mg q24h | 500 mg q24h | 500 mg q24h | 10–14 days; reserve for no alternative |
| AECB (reserve) | 500 mg q24h | 500 mg q24h | 500 mg q24h | 7 days; reserve for no alternative |
| Inhalational anthrax (post-exposure) | 500 mg q24h | 500 mg q24h | 500 mg q24h | 60 days (FDA PI) |
| Plague (Y. pestis) | 500 mg q24h | 500 mg q24h | 500 mg q24h | 10–14 days (FDA PI) |
Pediatric Dosing (FDA-approved indications only; ≥6 months)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Anthrax/Plague (≥50 kg) | 500 mg q24h | 500 mg q24h | 500 mg q24h | Anthrax 60 days; Plague 10–14 days (FDA PI) |
| Anthrax/Plague (30 to <50 kg; tablets) | 250 mg q12h | 250 mg q12h | 250 mg q12h | Tablets only (oral solution for <30 kg — not covered by tablet formulation) |
Renal Impairment Adjustments (Adults)
| Normal Dose | CrCl 20–49 mL/min | CrCl 10–19 mL/min | HD / CAPD | Notes |
|---|---|---|---|---|
| 750 mg q24h | 750 mg initial, then 500 mg q24h | 750 mg initial, then 500 mg q48h | 750 mg initial, then 500 mg q48h | FDA PI Table 3 |
| 500 mg q24h | 500 mg initial, then 250 mg q24h | 500 mg initial, then 250 mg q48h | 500 mg initial, then 250 mg q48h | FDA PI Table 3 |
| 250 mg q24h | No adjustment | No adjustment | No adjustment | No adjustment needed for 250 mg dose (FDA PI) |
Levofloxacin achieves ~99% oral bioavailability — essentially complete absorption. This means oral and IV doses are truly interchangeable at the same milligram dose, unlike ciprofloxacin (which requires higher oral doses to approximate IV exposure). This makes levofloxacin ideal for early IV-to-oral switch in pneumonia and allows most patients to receive the entire course orally if they can tolerate oral intake.
Pharmacology
Mechanism of Action
Levofloxacin is the active S-(-) enantiomer of racemic ofloxacin. Like ciprofloxacin, it exerts bactericidal activity by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, trapping these enzymes in complexes with cleaved DNA and triggering lethal double-strand breaks. However, levofloxacin’s enhanced potency against gram-positive organisms — particularly Streptococcus pneumoniae, including multi-drug-resistant strains (MDRSP) — distinguishes it as a “respiratory fluoroquinolone.” This broader gram-positive coverage also extends to staphylococci (MSSA) and enterococci. Levofloxacin retains the concentration-dependent killing kinetics characteristic of fluoroquinolones, where the AUC/MIC ratio best predicts clinical efficacy for respiratory and urinary infections.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | ~99% bioavailable (oral); Tmax 1–2 h; food has negligible effect on absorption; chelation with divalent/trivalent cations (Ca, Mg, Fe, Al) reduces absorption by up to 90% | Oral and IV doses are interchangeable at the same mg dose; take ≥2 h before or 2 h after antacids, iron, sucralfate, or multivitamins |
| Distribution | Vd ~1.1 L/kg; protein binding 24–38% (albumin); excellent penetration into lung, prostate, skin, bone; tissue concentrations generally exceed plasma; CSF penetration ~16% of plasma | High lung concentrations support pneumonia efficacy; good prostate penetration supports prostatitis use; tissue-to-plasma ratios >1 in most sites |
| Metabolism | Minimal hepatic metabolism (<5%); two minor metabolites (desmethyl-levofloxacin, N-oxide) with no relevant pharmacological activity; does NOT significantly inhibit CYP1A2 or other CYP enzymes | Major advantage over ciprofloxacin: no significant theophylline, tizanidine, or caffeine interactions. No hepatic dose adjustment needed. |
| Elimination | t½ 6–8 h; ~80–87% excreted renally as unchanged drug (glomerular filtration + tubular secretion); faecal <4% | Almost entirely renal elimination; dose reduction required at CrCl <50 mL/min; supports once-daily dosing; maintain hydration to prevent crystalluria |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| No individual AE ≥10% | — | No single adverse effect reaches ≥10% incidence in the pooled Phase 3 data (n=7,537). Most common AEs are in the 3–7% range (see below). |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 6.9% | Most common GI complaint; taking with food may help; dose-independent across 250–750 mg (FDA PI) |
| Headache | 6.0% | Usually mild and self-limiting |
| Diarrhea | 5.4% | Monitor for C. difficile if persistent or bloody |
| Insomnia | 4.1% | Fluoroquinolone class effect; morning dosing may reduce impact |
| Constipation | 3.1% | Usually mild |
| Dizziness | 2.8% | Advise caution with driving or machinery |
| Vomiting | 2.1% | Dose-related; more frequent at 750 mg |
| Abdominal pain | 2.0% | GI effects generally self-limiting |
| Rash | 1.8% | Discontinue if systemic features suggest hypersensitivity |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Tendinitis and tendon rupture [BOXED WARNING] | Uncommon; risk increased with age >60, corticosteroids, organ transplant | Hours to months; may occur after discontinuation | Discontinue immediately. Avoid exercise. Achilles tendon most commonly affected. |
| Peripheral neuropathy [BOXED WARNING] | Rare; may be irreversible | Days to weeks; may occur after first dose | Discontinue immediately if neuropathy symptoms develop (pain, burning, tingling, numbness). |
| CNS effects (seizures, psychosis, anxiety, depression, suicidal ideation, tremors) [BOXED WARNING] | Rare | Any time; may occur after first dose | Discontinue levofloxacin. Caution in patients with CNS disorders. Includes psychiatric reactions (hallucinations, paranoia, suicide attempts). |
| Myasthenia gravis exacerbation [BOXED WARNING] | Rare; may be fatal | Any time | Avoid in known myasthenia gravis. Discontinue if muscle weakness worsens. |
| Aortic aneurysm and dissection | Rare; epidemiological association | During or within months of therapy | Avoid in patients with known aortic aneurysm, Marfan, Ehlers-Danlos, or elderly with hypertension unless no alternative. |
| Hepatotoxicity (including fatal hepatic failure) | Rare; majority in patients ≥65 y | Usually within 14 days (most within 6 days) | Discontinue immediately if jaundice or hepatitis signs develop. Fatal cases reported, particularly in elderly. |
| QT prolongation / torsades de pointes | Rare | Any time | Avoid in known QT prolongation, hypokalaemia, or with Class IA/III antiarrhythmics. |
| Clostridioides difficile-associated diarrhea | Uncommon | During or up to 2 months after therapy | Stool C. difficile toxin assay; discontinue levofloxacin; treat appropriately |
| Hypersensitivity / anaphylaxis | Rare; sometimes fatal after first dose | After first or subsequent doses | Discontinue immediately; emergency treatment including epinephrine |
| Blood glucose disturbances | Uncommon | Any time; higher risk with concurrent antidiabetics | Monitor blood glucose in diabetic patients. Cases of hypoglycaemic coma reported. |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| GI intolerance (nausea, vomiting) | 1.4% | Most common reason across all doses (FDA PI) |
| Dizziness | 0.3% | Fluoroquinolone class effect |
| Headache | 0.2% | Usually self-limiting |
Fluoroquinolones, including levofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. These reactions can occur together in the same patient. Discontinue levofloxacin immediately and avoid fluoroquinolones in patients who experience any of these serious adverse reactions. Fluoroquinolones may exacerbate muscle weakness in patients with myasthenia gravis. Reserve levofloxacin for use in patients with uncomplicated UTI, AECB, and acute sinusitis who have no alternative treatment options.
Drug Interactions
Unlike ciprofloxacin, levofloxacin does not significantly inhibit CYP1A2 or other CYP450 enzymes. This eliminates the major theophylline, tizanidine, and caffeine interactions associated with ciprofloxacin. The primary interactions are chelation with polyvalent cations, modest warfarin enhancement, and dysglycaemia risk with antidiabetic agents.
Monitoring
- Renal FunctionBaseline; periodically during therapy
RoutineCrCl to guide dose adjustment (<50 mL/min requires reduction). Maintain hydration to prevent crystalluria. - Hepatic FunctionIf symptoms arise; heightened vigilance in patients ≥65 y
Trigger-basedFatal hepatotoxicity reported, predominantly in patients ≥65 y. Most cases within 14 days of initiation. Discontinue immediately if signs of hepatitis develop. - Tendon AssessmentOngoing throughout therapy
RoutineAsk about tendon pain, swelling, or stiffness. Risk highest in patients >60 y, on corticosteroids, or post-transplant. Discontinue immediately if symptoms arise. - Neurological StatusOngoing
RoutineAssess for peripheral neuropathy and CNS effects (seizures, tremors, psychosis, anxiety, depression, suicidal ideation). Discontinue if symptoms develop. - Blood GlucoseIn patients on antidiabetic agents
Trigger-basedBoth hypoglycaemia and hyperglycaemia reported. Cases of hypoglycaemic coma with concurrent sulfonylureas or insulin. - ECG / QTcIf risk factors for QT prolongation present
Trigger-basedMonitor in patients with known QT prolongation, hypokalaemia, hypomagnesaemia, or concurrent QT-prolonging drugs. Elderly may be more susceptible. - INR (if on warfarin)Within 3–5 days of starting
Trigger-basedMay enhance anticoagulant effect. Monitor and adjust warfarin dose as needed.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to levofloxacin or any fluoroquinolone antibiotic
Relative Contraindications (Specialist Input Recommended)
- Myasthenia gravis: May exacerbate muscle weakness; fatalities reported. Avoid unless no alternative (FDA boxed warning).
- Known aortic aneurysm or connective tissue disorder (Marfan, Ehlers-Danlos): Increased risk of aortic dissection.
- Known QT prolongation or concurrent Class IA/III antiarrhythmics: Risk of torsades de pointes.
- History of tendon disorders related to fluoroquinolone use: Do not re-challenge.
- Epilepsy or conditions predisposing to seizures: Fluoroquinolones lower seizure threshold.
Use with Caution
- Age >60 years: Increased risk of tendinopathy, hepatotoxicity, and QT prolongation.
- Concurrent corticosteroid use: Additive tendon injury risk.
- Organ transplant recipients: Elevated tendinopathy risk.
- Renal impairment (CrCl <50 mL/min): Dose reduction required.
- Diabetes: Dysglycaemia risk; monitor blood glucose closely.
- Pregnancy: Category C. Avoid if alternative available. Arthropathy risk in animals; limited human data suggests low risk.
- Pediatric patients: Only for anthrax and plague (≥6 months) due to musculoskeletal AE risk.
Fluoroquinolones, including levofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions including tendinitis and tendon rupture, peripheral neuropathy, and central nervous system effects. These reactions can occur together in the same patient. Discontinue levofloxacin immediately and avoid fluoroquinolones in patients who experience any of these serious adverse reactions. Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis. Avoid use in patients with a known history of myasthenia gravis. Reserve levofloxacin for patients with uncomplicated UTI, AECB, and acute bacterial sinusitis who have no alternative treatment options.
Patient Counselling
Purpose of Therapy
Levofloxacin is a powerful antibiotic that kills bacteria by damaging their DNA. It is used for serious infections including pneumonia, urinary tract infections, prostatitis, and skin infections. Complete the full course even if you feel better.
How to Take
Take levofloxacin once daily with or without food. Swallow tablets whole with a full glass of water and stay well hydrated. Avoid taking levofloxacin within 2 hours of antacids, iron supplements, calcium products, sucralfate, or multivitamins containing minerals, as these can prevent the antibiotic from working.
Sources
- LEVAQUIN (levofloxacin) Tablets — Full Prescribing Information. Revised 6/2020. accessdata.fda.govCurrent FDA label with boxed warning, complete dosing tables for all approved indications, renal adjustment table, and pooled Phase 3 adverse reaction data (n=7,537).
- Levofloxacin Injection — Full Prescribing Information (Eugia US). Revised 6/2024. drugs.com/proCurrent IV formulation label with infusion instructions and most common AEs (≥3%): nausea, headache, diarrhea, insomnia, constipation, dizziness.
- Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 2003;37(6):752-760. doi:10.1086/377539Pivotal RCT establishing 750 mg x 5 days as noninferior to 500 mg x 10 days for CAP, supporting high-dose short-course approach.
- Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open. 2015;5(11):e010077. doi:10.1136/bmjopen-2015-010077Large cohort study quantifying tendon rupture and aortic aneurysm risk with fluoroquinolone use in elderly patients.
- Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia: An Official Clinical Practice Guideline of the ATS and IDSA. Am J Respir Crit Care Med. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581STCurrent ATS/IDSA CAP guideline recommending respiratory fluoroquinolone monotherapy as alternative first-line for outpatient CAP with comorbidities or inpatient non-ICU CAP.
- Kalil AC, Metersky ML, Klompas M, et al. Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by IDSA and ATS. Clin Infect Dis. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353IDSA/ATS HAP/VAP guideline listing levofloxacin among empiric treatment options for nosocomial pneumonia.
- FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections. July 2016 (updated 2018). fda.govKey FDA safety communication restricting fluoroquinolones for uncomplicated UTI, sinusitis, and bronchitis when alternatives exist.
- Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53(10):1565-1574. doi:10.1021/bi5000564Detailed review of DNA gyrase and topoisomerase IV inhibition by fluoroquinolones, including concentration-dependent killing kinetics.
- Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997;61(3):377-392. doi:10.1128/mmbr.61.3.377-392.1997Foundational review of the dual-target mechanism of fluoroquinolone antibacterials.
- Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997;32(2):101-119. doi:10.2165/00003088-199732020-00002Comprehensive PK review establishing bioavailability (~99%), Vd (1.1 L/kg), t½ (6–8 h), protein binding (24–38%), and minimal metabolism.
- Levofloxacin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 (updated Mar 2024). ncbi.nlm.nih.govCurrent clinical pharmacology reference covering renal dosing, paediatric PK, drug interactions, and FDA boxed warning summary.